Glionova AB is a privately-held development stage biopharmaceutical company based in Stockholm, Sweden. We are dedicated to the development of innovative therapies for difficult-to-treat cancers using the company's unique expertise and proprietary technology. Our lead product, GLN-1001, is being developed for treating patients suffering from glioblastoma (GBM), the most common and most aggressive primary brain tumor. GBM is a devastating disease with marginal life expectancy and limited treatment options, necessitating the development of conceptually new therapeutic strategies.
We are developing a novel therapy aiming to selectively and efficiently kill GBM cells by targeting a newly discovered vulnerability of the cancer cells, namely catastrophic vacuolization. Our lead compound GLN-1001, currently in preclinical development, has been shown to efficiently deplete cancer cells in animal models of GBM and significantly prolong survival, without apparent effects on host brain. Through further development, GLN-1001 has the potential to provide improved clinical benefit for patients in dire need of new therapeutic options.
The company's management consists of a dynamic team of academic scientists, experienced drug developers, and business professionals.